Natalizumab is a humanized monoclonal antibody produced in murine myeloma cells of isotype IgG4k. Natalizumab contains a human framework region and a complementarity determining region of a murine antibody that binds to ?4-integrin. Natalizumab has been temporarily discontinued due to the risk of progressive multifocal leukoencephalopathy (PML).
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? *
Did it work in your application? *
Your review *
Save my name, email, and website in this browser for the next time I comment.
Send us a message from the form below
Lab / Company
Your cart is currently empty.